The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.
 
Sayed Matar
No Relationships to Disclose
 
Opeyemi Jegede
Research Funding - Bristol Myers Squibb Foundation
 
Thomas Denize
No Relationships to Disclose
 
Fatme Ghandour
No Relationships to Disclose
 
Yasmin Nabil Laimon
No Relationships to Disclose
 
Nourhan El Ahmar
No Relationships to Disclose
 
Aseman Bagheri Sheshdeh
No Relationships to Disclose
 
Varunika Savla
No Relationships to Disclose
 
Razan Assaad Mohanna
No Relationships to Disclose
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); Regeneron (Inst)
 
David A. Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Eisai; Elephas Bio; Exelixis; Insight Strategy; Link Cell Therapies; Merck; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Maxine Sun
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
 
Saurabh Gupta
Employment - Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgen (I); Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene (I)
 
Sai Vikram Vemula
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgen
 
Gordon J. Freeman
Stock and Other Ownership Interests - Bioentre; Geode Therapeutics; GV20 Oncotherapy; IgM Biosciences; Invaria; ITeos Therapeutics; Nextpoint; Triursus Therapeutics; Xios Therapeutics
Consulting or Advisory Role - Alixia (I); Amgen (I); Bicara Therapeutics (I); Bioentre; Bioentre (I); Corner Therapeutics (I); Elpiscience (I); Fibrogen (I); Geode Therapeutics; GlaxoSmithKline (I); GV20 Oncotherapy; IgM Biosciences; Iome (I); Iome Bio; ITeos Therapeutics; Janssen (I); Monopteros Therapeutics (I); Nextpoint; Santa Ana Bio; Selecta Biosciences (I); Simcere of America; SQZ Biotech (I); Surface Oncology (I)
Research Funding - Abbvie (I); Bristol-Myers Squibb; Calico (I); Erasca, Inc (I); Ipsen (I); Merck Sharp & Dohme (I); Moderna Therapeutics (I); Novartis (I); Quark (I); Roche/Genentech (I); Taiwan Bio (I); UCB (I); Vertex (I)
Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Dako; EMD Serono; Leica Biosystems; Mayo Clinic; Merck; Novartis; Novartis (I); Pfizer (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)
 
Robert J. Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pliant; Pyxis; Sanofi; Scholar Rock; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Cullinan Oncology; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Toni K. CHOUEIRI
Stock and Other Ownership Interests - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI